These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29414253)

  • 21. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
    Gromeier M; Brown MC; Zhang G; Lin X; Chen Y; Wei Z; Beaubier N; Yan H; He Y; Desjardins A; Herndon JE; Varn FS; Verhaak RG; Zhao J; Bolognesi DP; Friedman AH; Friedman HS; McSherry F; Muscat AM; Lipp ES; Nair SK; Khasraw M; Peters KB; Randazzo D; Sampson JH; McLendon RE; Bigner DD; Ashley DM
    Nat Commun; 2021 Jan; 12(1):352. PubMed ID: 33441554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Practical Consideration of Poliovirus as an Oncolytic Virotherapy.
    Denniston E; Crewdson H; Rucinsky N; Stegman A; Remenar D; Moio K; Clark B; Higginbotham A; Keffer R; Brammer S; Horzempa J
    Am J Virol; 2016; 5(1):1-7. PubMed ID: 28203321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study.
    Miller KE; Cassady KA; Roth JC; Clements J; Schieffer KM; Leraas K; Miller AR; Prasad N; Leavenworth JW; Aban IB; Whitley RJ; Gillespie GY; Mardis ER; Markert JM
    Clin Cancer Res; 2022 Feb; 28(3):498-506. PubMed ID: 35105718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncolytic viral therapy.
    Inam Ur Rehma S; Haaris SM
    J Pak Med Assoc; 2017 Apr; 67(4):658. PubMed ID: 28420939
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies.
    Haddad AF; Young JS; Mummaneni NV; Kasahara N; Aghi MK
    J Neurooncol; 2021 Mar; 152(1):1-13. PubMed ID: 33389564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune and viral therapies for malignant primary brain tumors.
    Gardeck AM; Sheehan J; Low WC
    Expert Opin Biol Ther; 2017 Apr; 17(4):457-474. PubMed ID: 28274139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic viruses: a novel form of immunotherapy.
    Prestwich RJ; Harrington KJ; Pandha HS; Vile RG; Melcher AA; Errington F
    Expert Rev Anticancer Ther; 2008 Oct; 8(10):1581-8. PubMed ID: 18925850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Active immunotherapy: oncolytic virus therapy using HSV-1.
    Todo T
    Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
    Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
    Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current Advances in Immunotherapy for Glioblastoma.
    Mende AL; Schulte JD; Okada H; Clarke JL
    Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
    Saha D; Martuza RL; Rabkin SD
    Immunotherapy; 2018 Jul; 10(9):779-786. PubMed ID: 30008259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diplomatic immunity: turning a foe into an ally.
    Parato KA; Lichty BD; Bell JC
    Curr Opin Mol Ther; 2009 Feb; 11(1):13-21. PubMed ID: 19169955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dichloroacetate blocks aerobic glycolytic adaptation to attenuated measles virus and promotes viral replication leading to enhanced oncolysis in glioblastoma.
    Li C; Meng G; Su L; Chen A; Xia M; Xu C; Yu D; Jiang A; Wei J
    Oncotarget; 2015 Jan; 6(3):1544-55. PubMed ID: 25575816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Kohlhapp FJ; Kaufman HL
    Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent Antitumor T-Cell Memory Is Generated by Curative Viral Oncolytic Immunotherapy But Not Curative Chemotherapy.
    Gao Y; Bergman I
    Anticancer Res; 2018 Dec; 38(12):6621-6629. PubMed ID: 30504370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies.
    Hamad A; Yusubalieva GM; Baklaushev VP; Chumakov PM; Lipatova AV
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
    Hamid O; Hoffner B; Gasal E; Hong J; Carvajal RD
    Cancer Immunol Immunother; 2017 Oct; 66(10):1249-1264. PubMed ID: 28712033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.